Lingling Tian
@linglingtian.bsky.social
Editor, Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social
Co-Editor, Rare Tumors | Clinical Medicine Insights: Oncology
Co-Editor, Rare Tumors | Clinical Medicine Insights: Oncology
Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors.
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
November 14, 2025 at 2:36 AM
Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors.
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
ADCs are transforming breast cancer care, but toxicity management remains key to patient outcomes. Read the full review 👉 buff.ly/Fp2c5JI #BreastCancer #Oncology #ADCs #CancerResearch
November 13, 2025 at 8:15 AM
ADCs are transforming breast cancer care, but toxicity management remains key to patient outcomes. Read the full review 👉 buff.ly/Fp2c5JI #BreastCancer #Oncology #ADCs #CancerResearch
How poor is the prognosis for dialysis-dependent #MultipleMyeloma? This multicenter study confirms it's severe, but also identifies a path to hope. Achieving dialysis independence TRIPLES median overall survival.
Key factors: VGPR, daratumumab, deep early light chain response.
Key factors: VGPR, daratumumab, deep early light chain response.
Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study - Ji-nuo Wang, Chenyun Wang, Jinping Ying, Gaofeng Zheng, Xiaoyan Han, Peng An, Gang Wang, Fei Chen, Li Yang, Yang Yang, Donghua He, Jingsong He, Yuanshuai Chen, Wenjun Wu, Zhen Cai, 2025
Background: Patients with multiple myeloma (MM) and renal impairment (RI), particularly those requiring dialysis, have historically experienced poor outcomes. D...
buff.ly
November 10, 2025 at 8:15 AM
How poor is the prognosis for dialysis-dependent #MultipleMyeloma? This multicenter study confirms it's severe, but also identifies a path to hope. Achieving dialysis independence TRIPLES median overall survival.
Key factors: VGPR, daratumumab, deep early light chain response.
Key factors: VGPR, daratumumab, deep early light chain response.
📢 Real-world data from China on T-DXd in HER2+ and HER2-low advanced breast cancer is here!
🧬 PFS ~10 months
📈 ORR: 62.5% (HER2+) | 37.9% (HER2-low)
✅ Manageable safety profile
T-DXd shows promise across HER2 expression levels. buff.ly/jrOE20b
#BreastCancer #HER2 #Oncology #RealWorldEvidence #TDXd
🧬 PFS ~10 months
📈 ORR: 62.5% (HER2+) | 37.9% (HER2-low)
✅ Manageable safety profile
T-DXd shows promise across HER2 expression levels. buff.ly/jrOE20b
#BreastCancer #HER2 #Oncology #RealWorldEvidence #TDXd
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
buff.ly
November 7, 2025 at 8:15 AM
📢 Real-world data from China on T-DXd in HER2+ and HER2-low advanced breast cancer is here!
🧬 PFS ~10 months
📈 ORR: 62.5% (HER2+) | 37.9% (HER2-low)
✅ Manageable safety profile
T-DXd shows promise across HER2 expression levels. buff.ly/jrOE20b
#BreastCancer #HER2 #Oncology #RealWorldEvidence #TDXd
🧬 PFS ~10 months
📈 ORR: 62.5% (HER2+) | 37.9% (HER2-low)
✅ Manageable safety profile
T-DXd shows promise across HER2 expression levels. buff.ly/jrOE20b
#BreastCancer #HER2 #Oncology #RealWorldEvidence #TDXd
🧠 SCLC remains one of the most aggressive cancers.
This new review explores:
🔹 ICIs
🔹 Novel agents like lurbinectedin
🔹 Anti-DLL3 therapies
🔹 Molecular profiling for personalized care
buff.ly/Mmx2f1V
Hope is on the horizon for ES-SCLC.
#LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy
This new review explores:
🔹 ICIs
🔹 Novel agents like lurbinectedin
🔹 Anti-DLL3 therapies
🔹 Molecular profiling for personalized care
buff.ly/Mmx2f1V
Hope is on the horizon for ES-SCLC.
#LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
buff.ly
November 5, 2025 at 8:15 AM
🧠 SCLC remains one of the most aggressive cancers.
This new review explores:
🔹 ICIs
🔹 Novel agents like lurbinectedin
🔹 Anti-DLL3 therapies
🔹 Molecular profiling for personalized care
buff.ly/Mmx2f1V
Hope is on the horizon for ES-SCLC.
#LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy
This new review explores:
🔹 ICIs
🔹 Novel agents like lurbinectedin
🔹 Anti-DLL3 therapies
🔹 Molecular profiling for personalized care
buff.ly/Mmx2f1V
Hope is on the horizon for ES-SCLC.
#LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy
🚨 A multicenter study compares mFOLFOX-6 vs. mDCF in metastatic gastric & GEJ cancer. buff.ly/1NsLmel
🔍 Similar efficacy
📉 Lower toxicity with mFOLFOX-6
📊 493 patients across 25 hospitals
Is doublet chemo the new standard?
#GastricCancer #Oncology #GIcancer #Chemotherapy #CancerResearch
🔍 Similar efficacy
📉 Lower toxicity with mFOLFOX-6
📊 493 patients across 25 hospitals
Is doublet chemo the new standard?
#GastricCancer #Oncology #GIcancer #Chemotherapy #CancerResearch
Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study - Ogur Karhan, Serdar İleri, Zuhat Urakçı, Yasin Sezgin, Ümit Yıldırım, Beyza Ünlü, Hacer Demir, Hasibe Bilge Gür, Ayşe Demirci, Melih Şimşek, Hüseyin Salih Semiz, Savaş Gökçek, Nilgün Yıldırım, Tuğçe Kübra Güneş, Abdilkerim Oyman, Tolga Doğan, Gamze Gököz Doğu, Yusuf İlhan, Özgür Tanrıverdi, Ali İnal, Nadiye Sever, Ezgi Türkoğlu, Tugay Avcı, Sadi Kerem Okutur, Pınar Peker, Doğan Bayram, Onur Yazdan Balçık, Pervin Can Şancı, Seray Saray, Pınar Çoban Eşdur, İsmail Beypınar, Sezai Tunç, 2025
Background: Metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer are associated with a poor prognosis. Recent advancements in treatment hav...
buff.ly
November 3, 2025 at 8:15 AM
🚨 A multicenter study compares mFOLFOX-6 vs. mDCF in metastatic gastric & GEJ cancer. buff.ly/1NsLmel
🔍 Similar efficacy
📉 Lower toxicity with mFOLFOX-6
📊 493 patients across 25 hospitals
Is doublet chemo the new standard?
#GastricCancer #Oncology #GIcancer #Chemotherapy #CancerResearch
🔍 Similar efficacy
📉 Lower toxicity with mFOLFOX-6
📊 493 patients across 25 hospitals
Is doublet chemo the new standard?
#GastricCancer #Oncology #GIcancer #Chemotherapy #CancerResearch
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World”
🗓️ Join the conversation on cancer care for older adults.
buff.ly/ASkDwOt
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World”
🗓️ Join the conversation on cancer care for older adults.
buff.ly/ASkDwOt
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
buff.ly
November 1, 2025 at 8:15 AM
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World”
🗓️ Join the conversation on cancer care for older adults.
buff.ly/ASkDwOt
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World”
🗓️ Join the conversation on cancer care for older adults.
buff.ly/ASkDwOt
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
This review outlines current therapies and future directions for KRAS G12C-mutant NSCLC
• Targeted inhibitors: sotorasib, adagrasib
• Immunotherapy combos: checkpoint inhibitors + KRAS blockade
• Dual ICI strategies under exploration
Read more: buff.ly/KdmExKt
#CancerResearch #NSCLC #KRASG12C
• Targeted inhibitors: sotorasib, adagrasib
• Immunotherapy combos: checkpoint inhibitors + KRAS blockade
• Dual ICI strategies under exploration
Read more: buff.ly/KdmExKt
#CancerResearch #NSCLC #KRASG12C
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
buff.ly
October 31, 2025 at 8:15 AM
This review outlines current therapies and future directions for KRAS G12C-mutant NSCLC
• Targeted inhibitors: sotorasib, adagrasib
• Immunotherapy combos: checkpoint inhibitors + KRAS blockade
• Dual ICI strategies under exploration
Read more: buff.ly/KdmExKt
#CancerResearch #NSCLC #KRASG12C
• Targeted inhibitors: sotorasib, adagrasib
• Immunotherapy combos: checkpoint inhibitors + KRAS blockade
• Dual ICI strategies under exploration
Read more: buff.ly/KdmExKt
#CancerResearch #NSCLC #KRASG12C
TAMO Article examines ctDNA in guiding chemo for stage II colon cancer. Findings? ctDNA combined with risk features enhances outcomes. Test cost, performance, and predictive value affect cost-effectiveness. More data needed on ctDNA's role in treatment response prediction. Read more:
Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer - Astrid Kramer, Marjolein J. E. Greuter, Suzanna J. Schraa, Geraldine R. Vink, Jillian Phallen, Victor E. Velculescu, Gerrit A. Meijer, Daan van den Broek, Miriam Koopman, Jeanine M. L. Roodhart, Remond J. A. Fijneman, Valesca P. Retèl, Veerle M. H. Coupé, 2024
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment...
buff.ly
October 29, 2025 at 8:15 AM
TAMO Article examines ctDNA in guiding chemo for stage II colon cancer. Findings? ctDNA combined with risk features enhances outcomes. Test cost, performance, and predictive value affect cost-effectiveness. More data needed on ctDNA's role in treatment response prediction. Read more:
A meta-analysis of 86 studies on immunotherapy in NSCLC reveals: KRAS G12C & MET amplification show strong responses; EGFR, ALK, HER2, RET, ROS1 exhibit limited benefit from monotherapy; combination therapies significantly improve outcomes. Read more: buff.ly/oH9GKGz #Cancer #NSCLC #Immunotherapy
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis - Jiayan Chen, Wanjun Lu, Mo Chen, Zijing Cai, Ping Zhan, Xin Liu, Suhua Zhu, Mingxiang Ye, Tangfeng Lv, Jiawen Lv, Yong Song, Dong Wang, 2024
Background: Immunotherapy is an emerging antitumor therapy that can improve the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, ...
buff.ly
October 27, 2025 at 8:15 AM
A meta-analysis of 86 studies on immunotherapy in NSCLC reveals: KRAS G12C & MET amplification show strong responses; EGFR, ALK, HER2, RET, ROS1 exhibit limited benefit from monotherapy; combination therapies significantly improve outcomes. Read more: buff.ly/oH9GKGz #Cancer #NSCLC #Immunotherapy
📊 Real-world data from Spain shows that nal-IRI + 5-FU/LV offers survival benefits for patients with advanced #PDAC, with outcomes comparable to clinical trials.
Dive into the full TAMO study: buff.ly/hOvxr4Q
#PancreaticCancer #RealWorldEvidence #TAMO #ESMO25 #OncologyResearch
Dive into the full TAMO study: buff.ly/hOvxr4Q
#PancreaticCancer #RealWorldEvidence #TAMO #ESMO25 #OncologyResearch
October 23, 2025 at 7:15 AM
📊 Real-world data from Spain shows that nal-IRI + 5-FU/LV offers survival benefits for patients with advanced #PDAC, with outcomes comparable to clinical trials.
Dive into the full TAMO study: buff.ly/hOvxr4Q
#PancreaticCancer #RealWorldEvidence #TAMO #ESMO25 #OncologyResearch
Dive into the full TAMO study: buff.ly/hOvxr4Q
#PancreaticCancer #RealWorldEvidence #TAMO #ESMO25 #OncologyResearch
As #ESMO25 wraps up, we celebrate the science - and the people behind it.
Huge congratulations to TAM Associate Editor Dr. Natasha Leighl on receiving the Women for Oncology Award!
A true leader in cancer care. 👏
#WomenInSTEM #OncologyLeadership
Huge congratulations to TAM Associate Editor Dr. Natasha Leighl on receiving the Women for Oncology Award!
A true leader in cancer care. 👏
#WomenInSTEM #OncologyLeadership
October 21, 2025 at 11:02 AM
As #ESMO25 wraps up, we celebrate the science - and the people behind it.
Huge congratulations to TAM Associate Editor Dr. Natasha Leighl on receiving the Women for Oncology Award!
A true leader in cancer care. 👏
#WomenInSTEM #OncologyLeadership
Huge congratulations to TAM Associate Editor Dr. Natasha Leighl on receiving the Women for Oncology Award!
A true leader in cancer care. 👏
#WomenInSTEM #OncologyLeadership
Following the buzz around #ESMO25?
Dive deeper with our review article - a timely read as we explore the future of ADCs.
🔗https://buff.ly/ovkYahi
#ADC #CancerTherapy #OncologyResearcH
Dive deeper with our review article - a timely read as we explore the future of ADCs.
🔗https://buff.ly/ovkYahi
#ADC #CancerTherapy #OncologyResearcH
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
buff.ly
October 19, 2025 at 7:15 AM
Following the buzz around #ESMO25?
Dive deeper with our review article - a timely read as we explore the future of ADCs.
🔗https://buff.ly/ovkYahi
#ADC #CancerTherapy #OncologyResearcH
Dive deeper with our review article - a timely read as we explore the future of ADCs.
🔗https://buff.ly/ovkYahi
#ADC #CancerTherapy #OncologyResearcH
🎉 #ESMO25 begins today!
While I’m not attending in person, I’ll be following the talks closely from Shanghai.
Looking forward to insights on #PrecisionOncology, #Immunotherapy, #ADCs and more.
Let’s connect and share highlights!
#OncologyCommunity #CancerResearch
While I’m not attending in person, I’ll be following the talks closely from Shanghai.
Looking forward to insights on #PrecisionOncology, #Immunotherapy, #ADCs and more.
Let’s connect and share highlights!
#OncologyCommunity #CancerResearch
October 17, 2025 at 10:01 AM
🎉 #ESMO25 begins today!
While I’m not attending in person, I’ll be following the talks closely from Shanghai.
Looking forward to insights on #PrecisionOncology, #Immunotherapy, #ADCs and more.
Let’s connect and share highlights!
#OncologyCommunity #CancerResearch
While I’m not attending in person, I’ll be following the talks closely from Shanghai.
Looking forward to insights on #PrecisionOncology, #Immunotherapy, #ADCs and more.
Let’s connect and share highlights!
#OncologyCommunity #CancerResearch
@tamedoncol.bsky.social
Navigating the Roadmap of New Treatment Options in HR+HER2- Advanced BC
Despite major advances, metastatic HR+HER2- BC remains incurable.
This Collection invites original research, reviews & meta-analyses
Deadline: Dec 01, 2025
🔗 buff.ly/etMC9S7
#Oncology #BreastCancer
Navigating the Roadmap of New Treatment Options in HR+HER2- Advanced BC
Despite major advances, metastatic HR+HER2- BC remains incurable.
This Collection invites original research, reviews & meta-analyses
Deadline: Dec 01, 2025
🔗 buff.ly/etMC9S7
#Oncology #BreastCancer
October 17, 2025 at 7:15 AM
@tamedoncol.bsky.social
Navigating the Roadmap of New Treatment Options in HR+HER2- Advanced BC
Despite major advances, metastatic HR+HER2- BC remains incurable.
This Collection invites original research, reviews & meta-analyses
Deadline: Dec 01, 2025
🔗 buff.ly/etMC9S7
#Oncology #BreastCancer
Navigating the Roadmap of New Treatment Options in HR+HER2- Advanced BC
Despite major advances, metastatic HR+HER2- BC remains incurable.
This Collection invites original research, reviews & meta-analyses
Deadline: Dec 01, 2025
🔗 buff.ly/etMC9S7
#Oncology #BreastCancer
Reposted by Lingling Tian
🎉 Honoring excellence in oncology!
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
Natasha Leighl, recipient of the 2025 ESMO Women for Oncology Award, will present her Award lecture at the #ESMO25 Opening Session. She will discuss key contributions to #LungCancer research & the role of liquid biopsy in #CancerDiagnostics.
📅 Opening Session https://ow.ly/BwMO50XavIS
📅 Opening Session https://ow.ly/BwMO50XavIS
October 17, 2025 at 5:10 AM
🎉 Honoring excellence in oncology!
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
CDK4/6 inhibitors are making waves in early breast cancer care. This guide explores how abemaciclib & ribociclib are being integrated into adjuvant therapy for HR+, HER2− EBC - plus tips on managing side effects & improving adherence.
Check it out: buff.ly/Lpmp3f0
#oncology #breastcancer #cdk46
Check it out: buff.ly/Lpmp3f0
#oncology #breastcancer #cdk46
Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer - Marya Hussain, Christine Brezden-Masley, Stephen Chia, Giuseppe Curigliano, Marc Webster, Jan-Willem Henning, 2025
The introduction of the cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib to the adjuvant setting marks a significant advancement ...
buff.ly
October 15, 2025 at 7:15 AM
CDK4/6 inhibitors are making waves in early breast cancer care. This guide explores how abemaciclib & ribociclib are being integrated into adjuvant therapy for HR+, HER2− EBC - plus tips on managing side effects & improving adherence.
Check it out: buff.ly/Lpmp3f0
#oncology #breastcancer #cdk46
Check it out: buff.ly/Lpmp3f0
#oncology #breastcancer #cdk46
🔍 PARP inhibitors in advanced prostate cancer @tamedoncol.bsky.social
✅ Effective in HRR-deficient mCRPC
🔗 Promising combos with ARSi, radiation, chemo & more
📘 Future directions explored
Read the review 👉 buff.ly/FPovbjB
#ProstateCancer #PARPi #Oncology
✅ Effective in HRR-deficient mCRPC
🔗 Promising combos with ARSi, radiation, chemo & more
📘 Future directions explored
Read the review 👉 buff.ly/FPovbjB
#ProstateCancer #PARPi #Oncology
Development of PARP inhibitors in advanced prostate cancer - Maria Teresa Bourlon, Paola Valdez, Elena Castro, 2024
The relatively high prevalence of alterations in the homologous recombination repair (HRR) pathway described in advanced prostate cancer provides a unique oppor...
buff.ly
October 14, 2025 at 7:15 AM
🔍 PARP inhibitors in advanced prostate cancer @tamedoncol.bsky.social
✅ Effective in HRR-deficient mCRPC
🔗 Promising combos with ARSi, radiation, chemo & more
📘 Future directions explored
Read the review 👉 buff.ly/FPovbjB
#ProstateCancer #PARPi #Oncology
✅ Effective in HRR-deficient mCRPC
🔗 Promising combos with ARSi, radiation, chemo & more
📘 Future directions explored
Read the review 👉 buff.ly/FPovbjB
#ProstateCancer #PARPi #Oncology
While monoimmunotherapy has limited impact in several subtypes, combination approaches show promise, especially in KRAS G12C, BRAF non-V600E, and MET-amplified cases.
Precision matters.
buff.ly/AyrHAkr
#NSCLC #Immunotherapy #Oncology
Precision matters.
buff.ly/AyrHAkr
#NSCLC #Immunotherapy #Oncology
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
buff.ly
October 12, 2025 at 7:15 AM
While monoimmunotherapy has limited impact in several subtypes, combination approaches show promise, especially in KRAS G12C, BRAF non-V600E, and MET-amplified cases.
Precision matters.
buff.ly/AyrHAkr
#NSCLC #Immunotherapy #Oncology
Precision matters.
buff.ly/AyrHAkr
#NSCLC #Immunotherapy #Oncology
🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:
buff.ly
October 10, 2025 at 7:15 AM
🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:
Zolbetuximab is gaining attention as a targeted therapy for CLDN18.2-positive gastric and GEJ cancers.
This review dives into the science behind Claudin18.2 and the clinical promise of zolbetuximab, backed by SPOTLIGHT and GLOW trial data.
buff.ly/ok6eO7y
#Oncology #GastricCancer #Zolbetuximab
This review dives into the science behind Claudin18.2 and the clinical promise of zolbetuximab, backed by SPOTLIGHT and GLOW trial data.
buff.ly/ok6eO7y
#Oncology #GastricCancer #Zolbetuximab
October 8, 2025 at 7:15 AM
Zolbetuximab is gaining attention as a targeted therapy for CLDN18.2-positive gastric and GEJ cancers.
This review dives into the science behind Claudin18.2 and the clinical promise of zolbetuximab, backed by SPOTLIGHT and GLOW trial data.
buff.ly/ok6eO7y
#Oncology #GastricCancer #Zolbetuximab
This review dives into the science behind Claudin18.2 and the clinical promise of zolbetuximab, backed by SPOTLIGHT and GLOW trial data.
buff.ly/ok6eO7y
#Oncology #GastricCancer #Zolbetuximab
🧬 Article collection on @tamedoncol.bsky.social: PARPi in Gynecologic Cancers. This collection highlights research on HRR genetic landscape, PARPi outcomes, oxaliplatin sequencing in BRCA-mutated ovarian cancer, and PARPi resistance with combination strategies. 📚 Explore more
buff.ly
October 7, 2025 at 7:15 AM
🧬 Article collection on @tamedoncol.bsky.social: PARPi in Gynecologic Cancers. This collection highlights research on HRR genetic landscape, PARPi outcomes, oxaliplatin sequencing in BRCA-mutated ovarian cancer, and PARPi resistance with combination strategies. 📚 Explore more
Lung cancer is varying by region in risks and traits. A new article examines carcinogens, genetic predisposition, and molecular epidemiology. We seek submissions on geographic differences in lung cancer. Deadline: Dec 31, 2025 🔗 buff.ly/JCo9lJP #CancerResearch #LungCancer #GlobalHealth
October 5, 2025 at 7:15 AM
Lung cancer is varying by region in risks and traits. A new article examines carcinogens, genetic predisposition, and molecular epidemiology. We seek submissions on geographic differences in lung cancer. Deadline: Dec 31, 2025 🔗 buff.ly/JCo9lJP #CancerResearch #LungCancer #GlobalHealth
🚨Call for Papers: @tamedoncol.bsky.social invites submissions on Antibody Drug Conjugates (ADCs) in Gynecologic Cancers. Led by Dr. Angélica Nogueira Rodrigues & Dr. Rowan Miller, this collection spotlights innovative ADC research in gynecologic oncology. 📥 Submit your work. buff.ly/RhdEIHX
October 3, 2025 at 7:15 AM
🚨Call for Papers: @tamedoncol.bsky.social invites submissions on Antibody Drug Conjugates (ADCs) in Gynecologic Cancers. Led by Dr. Angélica Nogueira Rodrigues & Dr. Rowan Miller, this collection spotlights innovative ADC research in gynecologic oncology. 📥 Submit your work. buff.ly/RhdEIHX
🌟 Discover our top-cited article at @tamedoncol.bsky.social on aberrant DNA methylation in cancer. This review delves into epigenetic influences from BRCA1 to ctDNA, highlighting diagnostic, prognostic, and therapeutic impacts. 📖 Read more 🌟 buff.ly/ZAp0iD3
October 1, 2025 at 7:15 AM
🌟 Discover our top-cited article at @tamedoncol.bsky.social on aberrant DNA methylation in cancer. This review delves into epigenetic influences from BRCA1 to ctDNA, highlighting diagnostic, prognostic, and therapeutic impacts. 📖 Read more 🌟 buff.ly/ZAp0iD3